Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 790 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk... October 27, 2020 Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... March 2, 2021 Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... June 30, 2021 Increased Risk of Cancer in Early Life Among Individuals with Autism... April 28, 2022 Load more HOT NEWS Urine test for bladder cancer being developed Why it’s difficult to estimate the number of extra cancer deaths... Celebrating 10 years of partnership with NIVEA Sun ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland
